Headline: Prelude Therapeutics Launches Phase I Trial of PRT12396 - FDA Approved

[Para 1: The Lead] Prelude Therapeutics Inc. (NASDAQ: PRTH), a clinical-stage biopharmaceutical company, has received FDA clearance to proceed with its Phase I trial for PRT12396, a novel therapeutic agent aimed at treating a specific genetic disorder. The trial is scheduled to begin enrollment on March 15, 2026, marking a significant step forward in the company's pipeline development. [Para 2-3: Supporting details & Context] Preliminary data from in vitro and animal studies indicate PRT12396 has the potential to significantly improve patient outcomes. The Phase I trial will evaluate the safety, tolerability, and preliminary efficacy of PRT12396 in up to 48 healthy volunteers. Financial markets reacted positively to the news, with PRTH's stock price increasing by 5% in after-hours trading. The company plans to report preliminary results by the end of the second quarter of 2026.